𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

✍ Scribed by Victoria J. Sinibaldi; Michael A. Carducci; Sandra Moore-Cooper; Menachem Laufer; Marianna Zahurak; Mario A. Eisenberger

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
403 KB
Volume
94
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicenter Phase II study of estramusti
Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma
✍ David J. Vaughn; Archie W. Brown Jr.; W. Graydon Harker; Sang Huh; Lance Miller; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Abstract ## BACKGROUND The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen‐independent prostate carcinoma (AIPC). ## METHODS Patients with progressive AIPC received 90 mg/m^2^ paclitaxel by 1‐ho

A Phase II trial of green tea in the tre
A Phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma
✍ Aminah Jatoi; Neil Ellison; Patrick A. Burch; Jeff A. Sloan; Shaker R. Dakhil; P 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Background: Recent laboratory and epidemiologic studies have suggested that green tea has antitumor effects in patients with prostate carcinoma. this phase ii trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma. ## Methods: This study, whi

Phase II trial of paclitaxel, estramusti
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t

A Phase I/II study of strontium-89 combi
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases
✍ Lance C. Pagliaro; Ebrahim S. Delpassand; Dallas Williams; Randall E. Millikan; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract ## BACKGROUND The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium‐89 to patients with androgen independent prostate carcinoma. ## METHODS Patients with androgen‐independent pr

Weekly paclitaxel, estramustine phosphat
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma : Results of a Minnie Pearl Cancer Research Network Phase II Trial
✍ Anthony A. Meluch; F. Anthony Greco; Lisa H. Morrissey; Eric L. Raefsky; Ronald 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract ## BACKGROUND The objective of the current study was to evaluate the efficacy and toxicity of weekly paclitaxel, oral etoposide, and estramustine phosphate in the treatment of patients with advanced, hormone‐refractory prostate carcinoma. ## METHODS Patients with hormone‐refractory p